Frances Priddy

5.4k total citations
45 papers, 1.6k citations indexed

About

Frances Priddy is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Frances Priddy has authored 45 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Infectious Diseases, 15 papers in Virology and 15 papers in Epidemiology. Recurrent topics in Frances Priddy's work include HIV/AIDS Research and Interventions (18 papers), HIV Research and Treatment (15 papers) and SARS-CoV-2 and COVID-19 Research (12 papers). Frances Priddy is often cited by papers focused on HIV/AIDS Research and Interventions (18 papers), HIV Research and Treatment (15 papers) and SARS-CoV-2 and COVID-19 Research (12 papers). Frances Priddy collaborates with scholars based in United States, Kenya and United Kingdom. Frances Priddy's co-authors include Jessica E. Haberer, Gaudensia Mutua, Peter Mugo, Johannes S. Gach, Pascal Poignard, Melissa Simek, Dennis R. Burton, Sanjay Phogat, Denise Wagner and Laura M. Walker and has published in prestigious journals such as Nature Communications, PLoS ONE and The Journal of Infectious Diseases.

In The Last Decade

Frances Priddy

40 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Frances Priddy United States 19 1.1k 672 607 323 291 45 1.6k
Sodsai Tovanabutra United States 28 1.5k 1.3× 765 1.1× 1.4k 2.3× 276 0.9× 282 1.0× 102 2.4k
Marcel E. Curlin United States 20 2.0k 1.8× 1.2k 1.8× 667 1.1× 257 0.8× 542 1.9× 52 2.3k
Jonathan D. Fuchs United States 21 698 0.6× 696 1.0× 381 0.6× 411 1.3× 181 0.6× 58 1.5k
William Kilembe United States 23 983 0.9× 527 0.8× 509 0.8× 571 1.8× 182 0.6× 102 1.6k
Dana Panteleeff United States 14 1.0k 0.9× 482 0.7× 989 1.6× 186 0.6× 106 0.4× 16 1.4k
Raman Gangakhedkar India 25 1.4k 1.2× 978 1.5× 548 0.9× 480 1.5× 464 1.6× 106 2.4k
Cynthia L. Gay United States 28 1.9k 1.7× 948 1.4× 1.8k 2.9× 258 0.8× 123 0.4× 110 3.0k
Lewis K. Schrager United States 22 1.5k 1.3× 889 1.3× 1.2k 2.0× 143 0.4× 92 0.3× 34 2.4k
Robert W. Eisinger United States 14 770 0.7× 556 0.8× 210 0.3× 210 0.7× 123 0.4× 24 1.2k
Ibrahima Ndoye Senegal 14 1.6k 1.4× 585 0.9× 1.4k 2.3× 236 0.7× 219 0.8× 23 2.1k

Countries citing papers authored by Frances Priddy

Since Specialization
Citations

This map shows the geographic impact of Frances Priddy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frances Priddy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frances Priddy more than expected).

Fields of papers citing papers by Frances Priddy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frances Priddy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frances Priddy. The network helps show where Frances Priddy may publish in the future.

Co-authorship network of co-authors of Frances Priddy

This figure shows the co-authorship network connecting the top 25 collaborators of Frances Priddy. A scholar is included among the top collaborators of Frances Priddy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frances Priddy. Frances Priddy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Girard, Bethany, Amparo L. Figueroa, Stephen C. De Rosa, et al.. (2025). mRNA-1273 COVID-19 vaccine induces CD4+ T-cell responses among solid organ transplant recipients. Frontiers in Immunology. 16. 1505871–1505871.
2.
Du, Jiejun, Lan Lan, Archana Kapoor, et al.. (2025). Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial. Nature Communications. 16(1). 6118–6118. 2 indexed citations
3.
Priddy, Frances, Spyros Chalkias, Brandon Essink, et al.. (2024). A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and children. Expert Review of Vaccines. 23(1). 862–878. 6 indexed citations
4.
Figueroa, Amparo L., Jamil Azzi, Bijan Eghtesad, et al.. (2024). Safety and Immunogenicity of the mRNA-1273 Coronavirus Disease 2019 Vaccine in Solid Organ Transplant Recipients. The Journal of Infectious Diseases. 230(3). e591–e600. 3 indexed citations
5.
Figueroa, Amparo L., Anne Yeakey, Weiping Deng, et al.. (2024). Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial. The Lancet Infectious Diseases. 25(2). 208–217. 1 indexed citations
6.
Follmann, Dean, Xiaowei Wang, Peter B. Gilbert, et al.. (2023). 1939. Who to Boost When: An Analysis of Dosing Interval and Age on COVID-19 Outcomes in the COVE Trial During the Delta and Omicron Waves. Open Forum Infectious Diseases. 10(Supplement_2).
7.
Koff, Wayne C., Tere Williams, Ralph S. Baric, et al.. (2021). Development and deployment of COVID-19 vaccines for those most vulnerable. Science Translational Medicine. 13(579). 51 indexed citations
8.
9.
Priddy, Frances, David Lewis, Hans Gelderblom, et al.. (2019). Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. The Lancet HIV. 6(4). e230–e239. 105 indexed citations
10.
Andriesen, Jessica, Sheana Bull, Janan Dietrich, et al.. (2017). Using Digital Technologies in Clinical HIV Research: Real-World Applications and Considerations for Future Work. Journal of Medical Internet Research. 19(7). e274–e274. 5 indexed citations
11.
Mutua, Gaudensia, Juliet Mpendo, William Kilembe, et al.. (2014). Major Negative Social Impacts Are Rare in Phase 1 HIV Vaccine Trials in Africa. AIDS Research and Human Retroviruses. 30(S1). A190–A191. 2 indexed citations
12.
Karita, Etienne, Julien Nyombayire, Matt A. Price, et al.. (2014). Prevalence of HIV, Sexual Transmitted Infections and High Risk Sexual Behaviors among Female Sex Workers in Kigali, Rwanda. AIDS Research and Human Retroviruses. 30(S1). A279–A279. 1 indexed citations
13.
Nyombayire, Julien, Etienne Karita, Dagna Laufer, et al.. (2014). Acceptability of Multiple Mucosal Specimen Collection in a Phase 1 HIV Vaccine Trial in Rwanda. AIDS Research and Human Retroviruses. 30(S1). A236–A236.
14.
15.
Mutua, Gaudensia, Eduard J. Sanders, Peter Mugo, et al.. (2012). Safety and Adherence to Intermittent Pre-Exposure Prophylaxis (PrEP) for HIV-1 in African Men Who Have Sex with Men and Female Sex Workers. PLoS ONE. 7(4). e33103–e33103. 133 indexed citations
16.
Omosa-Manyonyi, Gloria, Walter Jaoko, Omu Anzala, et al.. (2011). Reasons for Ineligibility in Phase 1 and 2A HIV Vaccine Clinical Trials at Kenya Aids Vaccine Initiative (KAVI), Kenya. PLoS ONE. 6(1). e14580–e14580. 14 indexed citations
17.
Excler, Jean‐Louis, Wasima Rida, Frances Priddy, et al.. (2010). AIDS Vaccines and Preexposure Prophylaxis: Is Synergy Possible?. AIDS Research and Human Retroviruses. 27(6). 669–680. 26 indexed citations
18.
Gill, Harvinder Singh, Samantha N. Andrews, Senthilkumar K. Sakthivel, et al.. (2009). Selective removal of stratum corneum by microdermabrasion to increase skin permeability. European Journal of Pharmaceutical Sciences. 38(2). 95–103. 55 indexed citations
19.
Harro, Clayton, Michael Robertson, Michelle Lally, et al.. (2008). Safety and Immunogenicity of Adenovirus-Vectored Near-Consensus HIV Type 1 Clade B gag Vaccines in Healthy Adults. AIDS Research and Human Retroviruses. 25(1). 103–114. 46 indexed citations
20.
Korenbrot, Carol C., Claire D. Brindis, & Frances Priddy. (1991). Trends in rates of live births and abortions following state restrictions on public funding of abortion.. PubMed. 105(6). 555–62. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sodsai Tovanabutra Breakdown of academic impact, for papers by Marcel E. Curlin Breakdown of academic impact, for papers by Jonathan D. Fuchs Breakdown of academic impact, for papers by William Kilembe Breakdown of academic impact, for papers by Dana Panteleeff Breakdown of academic impact, for papers by Raman Gangakhedkar Breakdown of academic impact, for papers by Cynthia L. Gay Breakdown of academic impact, for papers by Lewis K. Schrager Breakdown of academic impact, for papers by Robert W. Eisinger Breakdown of academic impact, for papers by Ibrahima Ndoye
Rankless by CCL
2026